Skip to main content
Premium Trial:

Request an Annual Quote

Skyline, Clavis Partner on Biomarkers for AML Drug

NEW YORK (GenomeWeb News) – Skyline Diagnostics and Clavis Pharma today announced a deal to investigate gene expression biomarkers that may help determine which patients will benefit from a drug compound being developed for treating acute myeloid leukemia.

Under the agreement Skyline will investigate the biomarkers for use with Clavis' elacytarabine, a novel elaidic acid derivative of cytarabine currently undergoing the CLAVELA phase III study for treating patients with relapsed/refractory AML. The study is an open-label, randomized, controlled trial to demonstrate the effectiveness of elacytarabine compared to other current therapies, according to Clavis' website.

Athos Gianella-Borradori, chief medical officer of the Oslo, Norway-based drug firm, said in a statement that Skyline's expertise "will be instrumental in searching for gene expression patterns that can be utilized in the further biomarker program for elacytarabine."

Financial and other terms of the deal were not disclosed.

Based in Rotterdam, The Netherlands, Skyline develops array-based diagnostics tests.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.